David Einhorn Gain Therapeutics, Inc. Call Options Transaction History
Greenlight Capital Inc
- $1.97 Billion
- Q4 2023
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GANX
# of Institutions
37Shares Held
4.57MCall Options Held
37.9KPut Options Held
0-
Jones Financial Companies Lllp677KShares$1.04 Million0.0% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$866,1780.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA534KShares$817,5580.0% of portfolio
-
Geode Capital Management, LLC Boston, MA290KShares$444,4060.0% of portfolio
-
Marshall Wace, LLP London, X0276KShares$422,9420.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $18.2M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...